Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) Stock Competitors & Peer Comparison

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, VRTX has a market cap of 121.5B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while VRTX trades at $478.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas VRTX's P/E ratio is 25.44. In terms of profitability, MIRM's ROE is -2.89%, compared to VRTX's ROE of +0.21%. Regarding short-term risk, MIRM is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check VRTX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, REGN has a market cap of 78.3B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while REGN trades at $760.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas REGN's P/E ratio is 16.67. In terms of profitability, MIRM's ROE is -2.89%, compared to REGN's ROE of +0.18%. Regarding short-term risk, MIRM is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check REGN's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas VRNA's P/E ratio is -102.80. In terms of profitability, MIRM's ROE is -2.89%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, MIRM is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check VRNA's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ARGX has a market cap of 52.5B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ARGX trades at $844.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ARGX's P/E ratio is 76.22. In terms of profitability, MIRM's ROE is -2.89%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, MIRM is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check ARGX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MIRM's ROE is -2.89%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MIRM is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check SGEN's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, RVMDW has a market cap of 41.8B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while RVMDW trades at $10.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas RVMDW's P/E ratio is -2.42. In terms of profitability, MIRM's ROE is -2.89%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, MIRM is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check RVMDW's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, RVMD has a market cap of 41.1B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while RVMD trades at $193.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas RVMD's P/E ratio is -27.36. In terms of profitability, MIRM's ROE is -2.89%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, MIRM is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check RVMD's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ONC has a market cap of 34.5B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ONC trades at $323.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ONC's P/E ratio is 72.26. In terms of profitability, MIRM's ROE is -2.89%, compared to ONC's ROE of +0.12%. Regarding short-term risk, MIRM is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check ONC's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ALNY has a market cap of 29.3B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ALNY trades at $219.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ALNY's P/E ratio is 39.46. In terms of profitability, MIRM's ROE is -2.89%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, MIRM is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check ALNY's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ROIV has a market cap of 25B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ROIV trades at $34.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ROIV's P/E ratio is -35.55. In terms of profitability, MIRM's ROE is -2.89%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, MIRM is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check ROIV's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while INCY trades at $120.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas INCY's P/E ratio is 16.21. In terms of profitability, MIRM's ROE is -2.89%, compared to INCY's ROE of +0.30%. Regarding short-term risk, MIRM is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check INCY's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, BNTX has a market cap of 23.1B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while BNTX trades at $91.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas BNTX's P/E ratio is -19.77. In terms of profitability, MIRM's ROE is -2.89%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, MIRM is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check BNTX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, MRNA has a market cap of 22.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while MRNA trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas MRNA's P/E ratio is -6.99. In terms of profitability, MIRM's ROE is -2.89%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, MIRM is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check MRNA's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while UTHR trades at $518.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas UTHR's P/E ratio is 19.15. In terms of profitability, MIRM's ROE is -2.89%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, MIRM is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check UTHR's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while INSM trades at $98.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas INSM's P/E ratio is -17.17. In terms of profitability, MIRM's ROE is -2.89%, compared to INSM's ROE of -1.30%. Regarding short-term risk, MIRM is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check INSM's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MIRM's ROE is -2.89%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, MIRM is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check BGNE's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MIRM's ROE is -2.89%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, MIRM is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check DNA-WT's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, GMAB has a market cap of 17.8B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while GMAB trades at $29.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas GMAB's P/E ratio is 20.88. In terms of profitability, MIRM's ROE is -2.89%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, MIRM is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check GMAB's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, NBIX has a market cap of 16.7B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while NBIX trades at $166.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas NBIX's P/E ratio is 24.00. In terms of profitability, MIRM's ROE is -2.89%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, MIRM is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check NBIX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, JAZZ has a market cap of 16.4B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while JAZZ trades at $261.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas JAZZ's P/E ratio is 20.34. In terms of profitability, MIRM's ROE is -2.89%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, MIRM is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check JAZZ's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, BBIO has a market cap of 16.1B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while BBIO trades at $82.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas BBIO's P/E ratio is -21.94. In terms of profitability, MIRM's ROE is -2.89%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, MIRM is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check BBIO's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ASND has a market cap of 15.2B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ASND trades at $244.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ASND's P/E ratio is -101.07. In terms of profitability, MIRM's ROE is -2.89%, compared to ASND's ROE of -56.42%. Regarding short-term risk, MIRM is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check ASND's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, EXEL has a market cap of 14.1B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while EXEL trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas EXEL's P/E ratio is 16.77. In terms of profitability, MIRM's ROE is -2.89%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, MIRM is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check EXEL's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ARWR has a market cap of 12.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ARWR trades at $89.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ARWR's P/E ratio is -41.67. In terms of profitability, MIRM's ROE is -2.89%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, MIRM is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check ARWR's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MIRM's ROE is -2.89%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MIRM is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check KRTX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, BMRN has a market cap of 11.7B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while BMRN trades at $60.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas BMRN's P/E ratio is 29.19. In terms of profitability, MIRM's ROE is -2.89%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, MIRM is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check BMRN's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, MDGL has a market cap of 11.7B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while MDGL trades at $507.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas MDGL's P/E ratio is -39.65. In terms of profitability, MIRM's ROE is -2.89%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, MIRM is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check MDGL's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while TECH trades at $72.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas TECH's P/E ratio is 37.16. In terms of profitability, MIRM's ROE is -2.89%, compared to TECH's ROE of +0.05%. Regarding short-term risk, MIRM is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check TECH's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas RNAM's P/E ratio is -17.39. In terms of profitability, MIRM's ROE is -2.89%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, MIRM is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check RNAM's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, SMMT has a market cap of 11B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while SMMT trades at $13.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas SMMT's P/E ratio is -8.60. In terms of profitability, MIRM's ROE is -2.89%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, MIRM is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check SMMT's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, AXSM has a market cap of 10.9B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while AXSM trades at $212.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas AXSM's P/E ratio is -55.40. In terms of profitability, MIRM's ROE is -2.89%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, MIRM is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check AXSM's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, HALO has a market cap of 9.9B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while HALO trades at $83.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas HALO's P/E ratio is 18.02. In terms of profitability, MIRM's ROE is -2.89%, compared to HALO's ROE of +1.26%. Regarding short-term risk, MIRM is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check HALO's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, CYTK has a market cap of 9.8B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while CYTK trades at $78.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas CYTK's P/E ratio is -13.48. In terms of profitability, MIRM's ROE is -2.89%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, MIRM is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check CYTK's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, KRYS has a market cap of 9.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while KRYS trades at $324.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas KRYS's P/E ratio is 43.42. In terms of profitability, MIRM's ROE is -2.89%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, MIRM is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check KRYS's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MIRM's ROE is -2.89%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MIRM is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check RXDX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ABVX trades at $125.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ABVX's P/E ratio is -65.62. In terms of profitability, MIRM's ROE is -2.89%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, MIRM is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check ABVX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, IONS has a market cap of 9.2B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while IONS trades at $55.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas IONS's P/E ratio is -32.02. In terms of profitability, MIRM's ROE is -2.89%, compared to IONS's ROE of -1.11%. Regarding short-term risk, MIRM is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check IONS's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas NUVL's P/E ratio is -21.79. In terms of profitability, MIRM's ROE is -2.89%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, MIRM is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check NUVL's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, SYRE has a market cap of 9.1B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while SYRE trades at $104.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas SYRE's P/E ratio is -50.45. In terms of profitability, MIRM's ROE is -2.89%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, MIRM is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check SYRE's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while CRNX trades at $83.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas CRNX's P/E ratio is -16.35. In terms of profitability, MIRM's ROE is -2.89%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, MIRM is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check CRNX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while PTGX trades at $135.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas PTGX's P/E ratio is -75.03. In terms of profitability, MIRM's ROE is -2.89%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, MIRM is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check PTGX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MIRM's ROE is -2.89%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, MIRM is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check IMGN's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while PRAX trades at $310.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas PRAX's P/E ratio is -23.19. In terms of profitability, MIRM's ROE is -2.89%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, MIRM is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check PRAX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, KYMR has a market cap of 8.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while KYMR trades at $104.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas KYMR's P/E ratio is -29.57. In terms of profitability, MIRM's ROE is -2.89%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, MIRM is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check KYMR's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MIRM's ROE is -2.89%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, MIRM is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check BPMC's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ALKS has a market cap of 8.3B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ALKS trades at $49.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ALKS's P/E ratio is 52.28. In terms of profitability, MIRM's ROE is -2.89%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, MIRM is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check ALKS's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while APGE trades at $134.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas APGE's P/E ratio is -30.99. In terms of profitability, MIRM's ROE is -2.89%, compared to APGE's ROE of -0.33%. Regarding short-term risk, MIRM is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check APGE's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas CERE's P/E ratio is -16.47. In terms of profitability, MIRM's ROE is -2.89%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MIRM is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check CERE's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, IMVT has a market cap of 8.1B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while IMVT trades at $39.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas IMVT's P/E ratio is -14.74. In terms of profitability, MIRM's ROE is -2.89%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, MIRM is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check IMVT's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, PCVX has a market cap of 7.9B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while PCVX trades at $54.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas PCVX's P/E ratio is -7.95. In terms of profitability, MIRM's ROE is -2.89%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, MIRM is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check PCVX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, TGTX has a market cap of 7.5B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while TGTX trades at $48.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas TGTX's P/E ratio is 16.75. In terms of profitability, MIRM's ROE is -2.89%, compared to TGTX's ROE of +0.84%. Regarding short-term risk, MIRM is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check TGTX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas MTSR's P/E ratio is -23.58. In terms of profitability, MIRM's ROE is -2.89%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, MIRM is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check MTSR's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, COGT has a market cap of 7.3B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while COGT trades at $42.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas COGT's P/E ratio is -20.30. In terms of profitability, MIRM's ROE is -2.89%, compared to COGT's ROE of -0.83%. Regarding short-term risk, MIRM is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check COGT's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while IBRX trades at $6.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas IBRX's P/E ratio is -8.18. In terms of profitability, MIRM's ROE is -2.89%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, MIRM is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check IBRX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while RYTM trades at $105.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas RYTM's P/E ratio is -33.80. In terms of profitability, MIRM's ROE is -2.89%, compared to RYTM's ROE of -2.01%. Regarding short-term risk, MIRM is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check RYTM's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas MRUS's P/E ratio is -17.05. In terms of profitability, MIRM's ROE is -2.89%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, MIRM is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check MRUS's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ACLX's P/E ratio is -28.27. In terms of profitability, MIRM's ROE is -2.89%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, MIRM is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check ACLX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas RETA's P/E ratio is -66.29. In terms of profitability, MIRM's ROE is -2.89%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MIRM is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check RETA's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ERAS has a market cap of 6.4B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ERAS trades at $18.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ERAS's P/E ratio is -19.76. In terms of profitability, MIRM's ROE is -2.89%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, MIRM is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check ERAS's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while BLTE trades at $157.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas BLTE's P/E ratio is -84.10. In terms of profitability, MIRM's ROE is -2.89%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, MIRM is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check BLTE's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while CGON trades at $71.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas CGON's P/E ratio is -30.64. In terms of profitability, MIRM's ROE is -2.89%, compared to CGON's ROE of -0.23%. Regarding short-term risk, MIRM is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check CGON's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas CNTA's P/E ratio is -22.63. In terms of profitability, MIRM's ROE is -2.89%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, MIRM is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check CNTA's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, XENE has a market cap of 6.2B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while XENE trades at $64.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas XENE's P/E ratio is -13.62. In terms of profitability, MIRM's ROE is -2.89%, compared to XENE's ROE of -0.49%. Regarding short-term risk, MIRM is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check XENE's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, LGND has a market cap of 6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while LGND trades at $300.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas LGND's P/E ratio is 36.07. In terms of profitability, MIRM's ROE is -2.89%, compared to LGND's ROE of +0.16%. Regarding short-term risk, MIRM is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check LGND's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, PTCT has a market cap of 5.8B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while PTCT trades at $69.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas PTCT's P/E ratio is -29.66. In terms of profitability, MIRM's ROE is -2.89%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, MIRM is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check PTCT's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while SRRK trades at $47.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas SRRK's P/E ratio is -13.31. In terms of profitability, MIRM's ROE is -2.89%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, MIRM is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check SRRK's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas CDTX's P/E ratio is -19.77. In terms of profitability, MIRM's ROE is -2.89%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, MIRM is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check CDTX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MIRM's ROE is -2.89%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MIRM is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check ABCM's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MIRM's ROE is -2.89%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MIRM is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check ISEE's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas APLS's P/E ratio is 38.35. In terms of profitability, MIRM's ROE is -2.89%, compared to APLS's ROE of +0.40%. Regarding short-term risk, MIRM is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check APLS's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while TVTX trades at $56.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas TVTX's P/E ratio is -254.64. In terms of profitability, MIRM's ROE is -2.89%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, MIRM is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check TVTX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while CRSP trades at $53.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas CRSP's P/E ratio is -10.39. In terms of profitability, MIRM's ROE is -2.89%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, MIRM is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check CRSP's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, DYN has a market cap of 4.8B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while DYN trades at $25.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas DYN's P/E ratio is -8.07. In terms of profitability, MIRM's ROE is -2.89%, compared to DYN's ROE of -0.64%. Regarding short-term risk, MIRM is more volatile compared to DYN. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check DYN's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while EWTX trades at $44.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas EWTX's P/E ratio is -26.93. In terms of profitability, MIRM's ROE is -2.89%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, MIRM is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check EWTX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas TERN's P/E ratio is -51.41. In terms of profitability, MIRM's ROE is -2.89%, compared to TERN's ROE of -0.20%. Regarding short-term risk, MIRM is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check TERN's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ACAD has a market cap of 4.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ACAD trades at $27.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ACAD's P/E ratio is 13.31. In terms of profitability, MIRM's ROE is -2.89%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, MIRM is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check ACAD's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, DFTX has a market cap of 4.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while DFTX trades at $42.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas DFTX's P/E ratio is N/A. In terms of profitability, MIRM's ROE is -2.89%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, MIRM is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check DFTX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, DNTH has a market cap of 4.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while DNTH trades at $110.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas DNTH's P/E ratio is -26.73. In terms of profitability, MIRM's ROE is -2.89%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, MIRM is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check DNTH's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, CAI has a market cap of 4.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while CAI trades at $16.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas CAI's P/E ratio is -88.56. In terms of profitability, MIRM's ROE is -2.89%, compared to CAI's ROE of +0.06%. Regarding short-term risk, MIRM is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check CAI's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas FOLD's P/E ratio is -161.00. In terms of profitability, MIRM's ROE is -2.89%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, MIRM is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check FOLD's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, CELC has a market cap of 4.5B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while CELC trades at $92.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas CELC's P/E ratio is -23.72. In terms of profitability, MIRM's ROE is -2.89%, compared to CELC's ROE of -2.45%. Regarding short-term risk, MIRM is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check CELC's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas AKRO's P/E ratio is -14.57. In terms of profitability, MIRM's ROE is -2.89%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, MIRM is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check AKRO's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while MANE trades at $107.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas MANE's P/E ratio is -34.17. In terms of profitability, MIRM's ROE is -2.89%, compared to MANE's ROE of -0.84%. Regarding short-term risk, MIRM is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check MANE's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MIRM's ROE is -2.89%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MIRM is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check ALPN's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ELVN has a market cap of 4.4B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ELVN trades at $61.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ELVN's P/E ratio is -36.59. In terms of profitability, MIRM's ROE is -2.89%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, MIRM is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check ELVN's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas OPT's P/E ratio is -1.52. In terms of profitability, MIRM's ROE is -2.89%, compared to OPT's ROE of +1.18%. Regarding short-term risk, MIRM is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check OPT's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas PRTC's P/E ratio is -3.78. In terms of profitability, MIRM's ROE is -2.89%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, MIRM is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check PRTC's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MIRM's ROE is -2.89%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MIRM is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check MRTX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ADPT trades at $24.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ADPT's P/E ratio is -45.46. In terms of profitability, MIRM's ROE is -2.89%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, MIRM is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check ADPT's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas CPRX's P/E ratio is 12.30. In terms of profitability, MIRM's ROE is -2.89%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, MIRM is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check CPRX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while VKTX trades at $32.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas VKTX's P/E ratio is -7.96. In terms of profitability, MIRM's ROE is -2.89%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, MIRM is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check VKTX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, DNLI has a market cap of 3.8B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while DNLI trades at $24.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas DNLI's P/E ratio is -8.39. In terms of profitability, MIRM's ROE is -2.89%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, MIRM is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check DNLI's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MIRM's ROE is -2.89%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MIRM is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check RYZB's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MIRM's ROE is -2.89%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MIRM is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check CBAY's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, ORKA has a market cap of 3.7B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while ORKA trades at $98.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas ORKA's P/E ratio is -50.58. In terms of profitability, MIRM's ROE is -2.89%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, MIRM is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check ORKA's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, TNGX has a market cap of 3.7B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while TNGX trades at $29.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas TNGX's P/E ratio is -35.37. In terms of profitability, MIRM's ROE is -2.89%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, MIRM is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for MIRM.Check TNGX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, RCUS has a market cap of 3.6B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while RCUS trades at $28.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas RCUS's P/E ratio is -8.85. In terms of profitability, MIRM's ROE is -2.89%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, MIRM is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check RCUS's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas SWTX's P/E ratio is -13.78. In terms of profitability, MIRM's ROE is -2.89%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, MIRM is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check SWTX's competition here

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MIRM stands at 6.4B. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, MIRM is priced at $104.33 on the NASDAQ, while LEGN trades at $19.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MIRM currently has a P/E ratio of -7.67, whereas LEGN's P/E ratio is -28.13. In terms of profitability, MIRM's ROE is -2.89%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, MIRM is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for MIRM.Check LEGN's competition here